Cover Image
市場調查報告書

全球抗生素市場

Global Antibiotics Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 312950
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
全球抗生素市場 Global Antibiotics Market 2014-2018
出版日期: 2014年09月17日 內容資訊: 英文 96 Pages
簡介

全球抗生素市場,預計從2013年到2018年之間,以1.41%的年複合成長率擴大。

本報告提供全球抗生素市場現狀及未來預測、作用機制、化學的各分類趨勢、市場成長要素與課題、主要供應商分析等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 抗生素的美國市場
  • 抗生素的歐洲市場
  • 抗生素的亞洲市場
  • 波特的五力分析

第7章 各作用機制的市場區隔

第8章 化學的各分類的市場區隔

第9章 地理區隔

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第18章 主要供應商分析

  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Eli Lilly and Co.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

第19章 相關報告

目錄
Product Code: IRTNTR4193

About Antibiotics

Antibacterial drugs are chemical compounds used to kill or inhibit the growth of bacteria. The term "antibiotic" is often used synonymously with antibacterial; however, the term "antibiotic" was originally coined to refer to the antibacterial compounds of microbial origin. Antibacterial acts via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis. It can be bacteriostatic or bactericidal in nature. Antibiotics are medicines that are used to treat infections caused by bacteria (e.g., respiratory tract infections). Antibiotics work against microorganisms such as bacteria, fungi, and parasites but are not effective against viruses. Antibiotics either block vital processes in bacteria, kill the bacteria, or halt them from growing. Antibiotics that affect a wide range of bacteria are called broad spectrum antibiotics (e.g., amoxicillin and gentamicin). Antibiotics that affect only a few types of bacteria are called narrow spectrum antibiotics (e.g., penicillin).

TechNavio's analysts forecast the Global Antibiotics market to grow at a CAGR of 1.41 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Antibiotics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various antibiotics for human use. The Global Antibiotics market can be divided into eight segments: Beta-lactams, Macrolides, Aminoglycosides, Phenicols, Quinolones, Sulfonamides, Tetracyclines, and Others.

TechNavio's report, the Global Antibiotics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Antibiotics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Bayer HealthCare
  • Bristol Myers Squibb
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • F. Hoffmann-La Roche
  • Takeda Pharmaceutical

Market Driver

  • Increased Aging Population

For a full, detailed list, view our report

Market Challenge

  • Emergence of Drug-resistant Strains

For a full, detailed list, view our report

Market Trend

  • Increase in Demand for Antibiotics

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05.Introduction

06.Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Antibiotics Market in the US
    • 06.3.1. Market Size and Forecast
  • 06.4. Antibiotics Market in Europe
    • 06.4.1. Market Size and Forecast
  • 06.5. Antibiotics Market in Asia
    • 06.5.1. Market Size and Forecast
  • 06.6. Five Forces Analysis

07. Market Segmentation by Mechanism of Action

  • 07.1. Introduction
  • 08. Market Segmentation by Chemical Class
    • 08.1. Market Segmentation by Drug Origin

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. AstraZeneca plc
    • 18.1.1. Key Facts
    • 18.1.2. Business Description
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Strategy
    • 18.1.5. Revenue by Business Segmentation
    • 18.1.6. Revenue Comparison 2011-2013
    • 18.1.7. Sales Revenue by Geographical Segmentation
    • 18.1.8. Key Developments
    • 18.1.9. SWOT Analysis
    • 18.1.10. Strengths
    • 18.1.11. Weaknesses
    • 18.1.12. Opportunities
    • 18.1.13. Threats
  • 18.2. GlaxoSmithKline plc
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.2.5. Sales by Geography
    • 18.2.6. Pipeline Products
    • 18.2.7. Business Strategy
    • 18.2.8. Key Information
    • 18.2.9. SWOT Analysis
    • 18.2.10. Strengths
    • 18.2.11. Weaknesses
    • 18.2.12. Opportunities
    • 18.2.13. Threats
  • 18.3. Eli Lilly and Co.
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.3.5. Sales by Geography
    • 18.3.6. Business Strategy
    • 18.3.7. Key Developments
    • 18.3.8. SWOT Analysis
    • 18.3.9. Strengths
    • 18.3.10. Weaknesses
    • 18.3.11. Opportunities
    • 18.3.12. Threats
  • 18.4. Johnson & Johnson
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2013
    • 18.4.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.4.5. Geographical Segmentation by Revenue 2013
    • 18.4.6. Business Strategy
    • 18.4.7. Recent Developments
    • 18.4.8. SWOT Analysis
    • 18.4.9. Strengths
    • 18.4.10. Weaknesses
    • 18.4.11. Opportunities
    • 18.4.12. Threats
  • 18.5. Novartis AG
    • 18.5.1. Key Facts
    • 18.5.2. Business Overview
    • 18.5.3. Business Segmentation by Revenue 2013
    • 18.5.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.5.5. Sales by Geography
    • 18.5.6. Business Strategy
    • 18.5.7. Key Developments
    • 18.5.8. SWOT Analysis
    • 18.5.9. Strengths
    • 18.5.10. Weaknesses
    • 18.5.11. Opportunities
    • 18.5.12. Threats
  • 18.6. Pfizer Inc.
    • 18.6.1. Key Facts
    • 18.6.2. Business Description
    • 18.6.3. Business Segmentation
    • 18.6.4. Revenue by Business Segmentation
    • 18.6.5. Revenue Comparison 2012KKKKK and 2013
    • 18.6.6. Sales by Geography
    • 18.6.7. Business Strategy
    • 18.6.8. Key Developments
    • 18.6.9. SWOT Analysis
    • 18.6.10. Strengths
    • 18.6.11. Weaknesses
    • 18.6.12. Opportunities
    • 18.6.13. Threats
  • 18.7. Sanofi
    • 18.7.1. Key Facts
    • 18.7.2. Business Overview
    • 18.7.3. Business Segmentation by Revenue 2013
    • 18.7.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.7.5. Geographical Segmentation by Revenue 2013
    • 18.7.6. Business Strategy
    • 18.7.7. Key Developments
    • 18.7.8. SWOT Analysis
    • 18.7.9. Strengths
    • 18.7.10. Weakness
    • 18.7.11. Opportunities
    • 18.7.12. Threats

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Antibiotics Market 2013-2018 (US$ million)
  • Exhibit 3: Antibiotics Market in the US 2013-2018 (US$ million)
  • Exhibit 4: Antibiotics Market in Europe 2013-2018 (US$ million)
  • Exhibit 5: Antibiotics Market in Asia 2013-2018 (US$ million)
  • Exhibit 6: Challenges Related to Antibiotic Development
  • Exhibit 7: Global Antibiotics Market Segmentation by Mechanism of Action
  • Exhibit 8: Global Antibacterial Drugs Market Segmentation by Chemical Class
  • Exhibit 9: Cephalosporin Segmentation by Generation of Drugs
  • Exhibit 10: Global Antibacterial Drugs Market Revenue Segmentation by Chemical Class 2013
  • Exhibit 11: Global Antibacterial Drugs Market Segmentation by Chemical Class in Volume 2013
  • Exhibit 12: Global Antibacterial Drugs Market Segmentation by Drug Origin
  • Exhibit 13: Global Antibiotics Market by Geographical Segmentation 2013
  • Exhibit 14: J&J Market Sales by Therapeutic Area (Pharmaceuticals) 2013
  • Exhibit 15: J&J Market Sales by Major Franchise (Medical Devices and Diagnostics) 2013
  • Exhibit 16: Abbott Laboratories by Revenue 2013
  • Exhibit 17: AstraZeneca plc: Business Segmentation
  • Exhibit 18: AstraZeneca plc: Revenue by Business Segmentation2013
  • Exhibit 19: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 20: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 21: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 22: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 23: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 24: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 25: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 26: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 27: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 28: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 29: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 30: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 31: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 32: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 33: Novartis AG: Sales by Geography 2013
  • Exhibit 34: Pfizer Inc.: Business Segmentation
  • Exhibit 35: Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 36: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 37: Pfizer Inc.: Revenue by Geography 2013
  • Exhibit 38: Sanofi: Business Segmentation by Revenue 2013
  • Exhibit 39: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 40: Sanofi: Geographical Segmentation by Revenue 2013
Back to Top